TCL Archive Two Conflicting Studies Presented at ASCO 2013, FDA Called Upon To Sort Through The Data June 28, 2013
TCL Archive Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint March 29, 2013
TCL Archive FDA seeks support for reorganization of cancer programs, but debate continues. July 9, 2004
